First multi-test capability added to proprietary MicroSlide technology

April 11, 2019

Ortho Clinical Diagnostics’ VITROS XT MicroSlides, featuring new, multi-test technology that allows labs to run two tests simultaneously on one MicroSlide, have been cleared for market by the FDA.

The product pairs tests that physicians typically order together, while maintaining the results that physicians expect from Ortho’s MicroSlide technology. Available test pairs include triglycerides and cholesterol; urea and creatinine; and glucose and calcium.

By pairing commonly ordered tests so they can be run simultaneously, Ortho’s VITROS XT MicroSlides, which are available for use on Ortho’s VITROS XT 7600 Integrated System, improve performance and productivity in the clinical lab, enabling a higher test throughput without requiring additional or larger analyzers. This is a benefit in a hospital environment, where space is often at a premium.

In addition, the miniaturized testing areas on each MicroSlide require less patient blood sample for each of the paired tests, an important advantage for vulnerable patients or those with venous access issues.

Ortho’s VITROS XT MicroSlides are powered by DIGITAL CHEMISTRY technology, available in the VITROS XT 7600 Integrated System, which uses advanced optics to glean significantly more information from each test than was possible before.

Ortho’s VITROS XT MicroSlides, which include VITROS XT UREA-CREA, TRIG-CHOL and GLU-Ca Slides, have been cleared by the FDA. In addition, they have received CE Mark, signifying conformance to applicable European Union regulatory requirements. These products are available on the VITROS XT 7600 Integrated System in numerous countries.

Visit Ortho Clinical for the release